Welcome to our dedicated page for Leap Therapeutics news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutics stock.
Leap Therapeutics, Inc. (Nasdaq: LPTX) is a pioneering clinical-stage biopharmaceutical company focused on developing novel targeted antibody therapies for cancer treatment. Headquartered in Cambridge, Massachusetts, Leap Therapeutics aims to discover and advance transformative cancer treatments by targeting tumor-promoting pathways, cancer-specific cell surface molecules, and activating the immune system against cancer cells.
The company's lead program, DKN-01, is a humanized monoclonal antibody that targets Dickkopf-related protein 1 (DKK1). This promising candidate is in clinical trials for treating esophagogastric, gynecologic, and colorectal cancers. Another key program, FL-301, targets Claudin18.2-expressing cells and is being developed for gastric and pancreatic cancer treatments. Leap Therapeutics also has two preclinical antibody programs, FL-302 and FL-501, which are advancing toward developing innovative cancer therapies.
Operating as a single segment dedicated to oncology, Leap Therapeutics has established several strategic collaborations to enhance its development pipeline, including a clinical collaboration with BeiGene for the DisTinGuish trial and partnerships with NovaRock Biotherapeutics and Adimab. The company's dedication to advancing targeted and immuno-oncology therapeutics underscores its commitment to addressing unmet needs in cancer treatment. Leap's research and development activities continue to make significant progress, with ongoing clinical trials and new data demonstrating the potential efficacy and safety of its therapeutic candidates.
In recent news, Leap Therapeutics announced the completion of enrollment in the randomized controlled Part C of the DisTinGuish study, evaluating DKN-01 in combination with tislelizumab and chemotherapy for advanced gastroesophageal junction and gastric cancer. Additionally, the company reported financial results for the first quarter of 2024, highlighting a successful $40 million financing that extends its cash runway into the second quarter of 2026. This funding will support the expansion and continued execution of the DKN-01 development program, including the expansion of the randomized controlled Part B of the DeFianCe study in second-line colorectal cancer patients.
For more information about Leap Therapeutics, visit www.leaptx.com or view their public filings with the SEC available via EDGAR at www.sec.gov or www.investors.leaptx.com.
Leica Biosystems has partnered with Leap Therapeutics (NASDAQ: LPTX) to create a companion diagnostic for detecting Dickkopf-related protein 1 (DKK1), a protein associated with poor cancer outcomes. This diagnostic will support the clinical development of Leap's DKN-01 therapy, a humanized monoclonal antibody currently in Phase 2 trials for gastric cancer. The test employs RNAscope™ technology to identify patients likely to benefit from DKN-01. This collaboration aims to enhance personalized cancer treatment based on biomarker profiles.
Leap Therapeutics (Nasdaq: LPTX), a biotechnology firm specializing in targeted and immuno-oncology therapies, will present a corporate overview at the B. Riley Securities Oncology Investor Conference on January 27, 2022, at 10:00 a.m. Eastern Time. The event will be virtual and accessible via the company’s website, where a replay will also be available. Leap's leading candidate, DKN-01, targets the Dickkopf-1 protein and is currently in clinical trials for various cancers. A partnership with BeiGene has been established for developing DKN-01 in Asia, Australia, and New Zealand.
Leap Therapeutics (Nasdaq: LPTX) announced that updated data from the DisTinGuish Phase 2a trial will be presented at the ASCO Gastrointestinal Cancers Symposium from January 20-22, 2022. The trial evaluates DKN-01, an anti-DKK1 antibody, combined with BeiGene's tislelizumab in patients with gastric and gastroesophageal junction cancer. Notable findings show promising efficacy in DKK1-high patients and improved safety tolerability. A conference call is scheduled for January 21, 2022, to discuss the results. The study is ongoing, focusing on both first-line and second-line therapies.
Leap Therapeutics (Nasdaq: LPTX) announced that its President and CEO, Douglas E. Onsi, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. The presentation will be available on January 10 at 7:00 a.m. Eastern Time via their Investors page.
The company focuses on developing targeted and immuno-oncology therapeutics, with DKN-01 as their lead candidate currently in trials for various cancers.
Leap Therapeutics (Nasdaq: LPTX) will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:00 a.m. Eastern Time. Douglas E. Onsi, President and CEO, will lead the presentation, which will be accessible via a live webcast on the company's Investors page. Leap Therapeutics focuses on developing targeted therapies, including DKN-01, a monoclonal antibody in clinical trials for various cancers. For more information, visit www.leaptx.com.
Leap Therapeutics, Inc. (Nasdaq: LPTX) announced participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. Members of the senior management team will engage in a fireside chat, with a replay available on the company’s Investors page starting November 22, 2021, at 10:00 a.m. ET. Leap is focused on developing targeted immuno-oncology therapeutics, with its lead candidate, DKN-01, currently in trials for various cancers. For more details, visit Leap's website.
Leap Therapeutics (Nasdaq:LPTX) reported its third quarter financial results for 2021, revealing a net loss of $11.1 million, up from $7.1 million in Q3 2020. The company successfully completed a $103.6 million public offering, netting $96.8 million. Positive initial data from the DisTinGuish Study of DKN-01 plus tislelizumab indicated a 68.2% overall response rate in first-line gastric cancer patients. R&D expenses rose to $10.1 million, attributed to increased clinical trial costs and staffing. Cash and equivalents stood at $124.8 million as of September 30, 2021.
Leap Therapeutics, Inc. (Nasdaq:LPTX) closed a public offering of 27,568,072 shares of common stock, raising approximately $104 million. This amount includes $7.25 million from collaborator BeiGene, Ltd. The offering included the additional sale of 4,740,000 shares due to underwriters' exercised options and 8,771,928 pre-funded warrants. Piper Sandler, Raymond James, and Mizuho acted as book-running managers. Proceeds will assist in advancing Leap's clinical programs, particularly for their leading candidate, DKN-01, which targets various cancers.
Leap Therapeutics (Nasdaq:LPTX) announced a public offering of common stock priced at $2.85 per share, alongside pre-funded warrants at $2.849 each. This offering is projected to raise approximately $90 million in gross proceeds, anticipated to close around September 24, 2021. The company will use the funds for further development of its drug candidate DKN-01, manufacturing clinical trial materials, and general corporate purposes. The offering includes an option for underwriters to purchase an additional 4,740,000 shares.
Leap Therapeutics (Nasdaq:LPTX) announced a proposed public offering of common stock and pre-funded warrants on Sept. 21, 2021. The offering will include a 30-day option for underwriters to purchase an additional 15%. Proceeds will fund the development of DKN-01, manufacturing clinical trial materials, and general corporate purposes. The offering is subject to market and regulatory conditions. Piper Sandler, Raymond James, and Mizuho Securities will act as book-running managers. The securities are part of an effective shelf registration.
FAQ
What is the current stock price of Leap Therapeutics (LPTX)?
What is the market cap of Leap Therapeutics (LPTX)?
What does Leap Therapeutics, Inc. specialize in?
What is DKN-01?
What are the latest developments in Leap Therapeutics' clinical trials?
Who are Leap Therapeutics' collaboration partners?
What are the financial highlights from Leap Therapeutics' latest quarter?
Where is Leap Therapeutics headquartered?
What is FL-301?
How does Leap Therapeutics plan to use the recent $40 million financing?
What are Leap Therapeutics' preclinical programs?
How can one access Leap Therapeutics' public filings?
